Lu AA24493 is in clinical phase II in the treatment of Friedreich's ataxia and
in clinical phase I in the treatment of acute ischaemic stroke. Ongoing studies
in both programmes are expected to be concluded in the second half of 2010.
Liestal, Switzerland, August 13, 2010 - Santhera Pharmaceuticals (SIX: SANN)
announced today that the European Patent Office granted patent protection for
the use of idebenone (brand name Catena®/Sovrima®) in the treatment of Duchenne
Muscular Dystrophy and other muscular dystrophies.